Although the expression of an inducible Fra-1 shRNA showed that regression of established tumor xenografts can be triggered by Fra-1 downregulation [37], Fra-1 silencing by exogenously administered siRNAs has not been tested yet in preclinical models. This evidence concerns the gene FOSL1 and neoplasm.